CMS Makes Corrections to 2017 HCPCS Level II

CMS Makes Corrections to 2017 HCPCS Level II

In a ritual as sure as the sunrise, the Centers for Medicare & Medicaid Services (CMS) has released corrections to HCPCS Level II codes. Although fewer than in some years, they are again too late to make it into publishers’ 2017 HCPCS Level II coding books, which were rushed to print after the codes were released November 5th. Please keep these updates with your books.

Changes include the addition of a retinal prosthesis code and two drug test codes. G0477-G0479, added last year after books were released, are deleted. All changes are effective January 1, 2017.

CODE ACTION LONG DESC
C1842 Added Retinal prosthesis, includes all internal and external components; add-on to C1841
E0627 Remove xref code Q0080
E0628 Remove xref code Q0078
E0629 Remove xref code Q0079
G0477 Deleted
G0478 Deleted
G0479 Deleted
G0480 Revise Long Description Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed
G0481 Revise Long Description Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed

 

 

Brad Ericson

Brad Ericson

Publisher at AAPC
Brad Ericson, MPC, CPC, COSC, 2017 AAPC MACRA Proficient,has been publisher for more than nine years. Before AAPC he was at Optum for 13 years and Aetna Health Plans prior to that. He has been writing and publishing about healthcare since 1979. He received his Bachelor's in Journalism from Idaho State University and his Master's of Professional Communication degree from Westminster College of Salt Lake City.
Brad Ericson

Latest posts by Brad Ericson (see all)

About Has 240 Posts

Brad Ericson, MPC, CPC, COSC, 2017 AAPC MACRA Proficient, has been publisher for more than nine years. Before AAPC he was at Optum for 13 years and Aetna Health Plans prior to that. He has been writing and publishing about healthcare since 1979. He received his Bachelor's in Journalism from Idaho State University and his Master's of Professional Communication degree from Westminster College of Salt Lake City.

Leave a Reply

Your email address will not be published. Required fields are marked *